Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
Bengisu AkbilTim MeyerPaula StubbemannCharlotte ThibeaultOlga StaudacherDaniela NiemeyerJenny JansenBarbara MühlemannJan DoehnChristoph TabelingChristian NusshagCédric HirzelDavid Sökler SanchezAlexandra NietersAchim LotherDaniel DuerschmiedNils SchallnerJan Nikolaus LieberumDietrich AugustSiegbert RiegValeria FalconeHartmut HengelUwe KölschNadine UnterwalderRalf-Harto HübnerTerry C JonesNorbert SuttorpChristian DrostenKlaus WarnatzThibaud SpinettiJoerg C SchefoldThomas DörnerLeif Erik SanderVictor M CormanUta Merlenull nullFlorian KurthHorst von BernuthChristian MeiselChristine GoffinetPublished in: Journal of clinical immunology (2022)
IFN-AABs may serve as early biomarker for the development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies.